• V. D. Lukianchuk Institute of Pharmacology and Toxicology of NAMS of Ukraine, Kyiv, Ukraine
  • I. I. Seifullina Odesa I. I. Mechnikov National University, Odesa
  • O. E. Martsinko Odesa I. I. Mechnikov National University, Odesa, Ukraine
  • O. O. Shevchuk Ternopil State Medical University, Ternopil
Keywords: global brain ischemia, germanium coordination compounds, screening.


Background. Stroke is among the leading causes of death and disability worldwide with rising incidence among young people today. This is the third most common cause of disability-adjusted life-years worldwide

Objective. The present study evaluated the cerebroprotective action of coordination compounds of germanium with underlying global cerebral ischemia in rats.

Methods. Global cerebral infarction was induced by bilateral common carotid artery occlusion. For primary screening we used numerous bis(citrate) germanates (stannates) compounds, which contained different metals: OL1-8, and VITAGERM-1,2,3 and 4. All germanium complexes used were injected intraperitoneally (1 % aqueous solution at a dose of 50 and 100 mg/kg in 35 min after bilateral common carotid artery occlusion). Piracetam was used as a reference drug. Criteria of cerebroprotection efficacy: survival of rats (%), ET50 (median effective time), observational Irwin’s test.

Results. Almost all bis(citrate) germanates (stannates), which contained different metals, possessed anti-ischemic activity of different intensity. The exceptions were cobalt-containing OL-6 and OL-2 compounds. The most significant efficacy of all investigated indices (which exceeded even reference drug) was evidenced for VITAGERM-1 – a coordination compound of germanium, diethylenetriaminepentaacetic acid and lithium.

Conclusions. Results of our experiments are the substitution for further more profound pharmacological investigation of VITAGERM-1 for stroke cerebroprotection and its implementation into clinics.

Author Biography

O. O. Shevchuk, Ternopil State Medical University, Ternopil
MD, PhD, assistant-professor of Pharmacology and Clinical Pharmacology Department


World Health organization WHO updates fact sheet on Top 10 causes of Death. 27 Jan 2017.

Zozulia IS. Epidemiology of cerebrovascular diseases in Ukraine. Ukrainian Medical Journal. 2011;85(5):38–41 [In Ukrainian].

Smajlovic D Strokes in young adults epidemiology and prevention. Vascular Health and Risk Management. 2015;11:157–164. doi.org/10.2147/VHRM.S53203. Feb 2015.

Musuka TD Wilton SB Traboulsi M Hill MD Diagnosis and management of acute ischemic stroke: speed is critical. CMAJ : Canadian Medical Association Journal. 2015;187(12):887–893. doi.org/10.1503/cmaj.140355. Aug 2015.

Sas A, Horvath L, Olah C, Valikovics A. A. Review of Neuroinflammatory Mechanisms in Ischemic Stroke: Background and Therapeutic Approaches. InMechanisms of Neuroinflammation. 2017. InTech.

Lukianchuk VD, Zhytina IO, Seifullina II, Martsinko OE, Pesaroglo OG. Screening and com- parative characteristic of anti ischemic e cacy of coordination compounds of germanium in acute cerebrovascular insuficiency Pharmacology and Drug Toxicology [In Ukrainian].

Lukianchuk VD, Krylova EV, Seifullina II, Tkachenko VN. Screening of potential cerebro- protectors among newly synthesized coordination compounds of germanium with complexions of hydroxycarboxylic acids in the model of global cerebral ischemia. GO Mozhaev Journal of Emergency Medicine. 2008;9(4):123–126 [In Russian].

Gad SC. Drug safety evaluation. John Wiley & Sons. Accessed 7 Nov 2016.

Stefanov OV. Preclinical study of drugs: methodical instructions. K: Avicenna. 2001:292–306.

Chadova LV, Seifulina II, Tkachenko VM. Screening and comparative characteristic of anti­ischemic drugs among coordination compounds of germanium with bioligands in acute cerebrovascular insufficiency. Odesa Medical Journal. 2005;6:19–22 [In Ukrainian].

Lukianchuk VD, Seifullina II, Litvinenko DF, Martsinko OE. Pharmacodynamics of organic and coordination compounds of germanium – modern state of art Pharmacology and Drug Toxicology. 2016;1:3–13 [In Ukrainian].

Shutka AO, Kravets DS, Lukianchuk VD. Mathematical-pharmacological analysis of dose regimen of new antihypoxant OK Ukrainian Journal of Cliniacll and Laboratory Medicine. 2010;5(4):115–9.

Canazza A, Minati L, Boffano C, Parati E, Binks S. Experimental models of brain ischemia a review of techniques, magnetic resonance imaging, and investigational cell-based therapies. Front Neurol. Frontiers Media SA. 2014;5:19.

Durukan A, Tatlisumak T. Acute ischemic stroke overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacology Biochemistry and Behavior. 2007;87(1):179–97.

Fluri F, Schuhmann MK, Kleinschnitz C. Animal models of ischemic stroke and their application in clinical research. Drug design, development and therapy. 2015;9:3445.

Winblad B Piracetam a review of phar macological properties and clinical uses. CNS Drug Rev. 2005;11(2):169–82.

Navarro-Mabarak C, Camacho-Carranza R, Espinosa-Aguirre JJ. Cytochrome P450 in the central nervous system as a therapeutic target in neurodegenerative diseases. Drug Metabolism Reviews. 2018;50(2):95–108.

How to Cite
Lukianchuk, V. D., Seifullina, I. I., Martsinko, O. E., & Shevchuk, O. O. (2018). CEREBROPROTECTION BY GERMANIUM COORDINATION COMPOUNDS IN EXPERIMENTAL ACUTE GLOBAL BRAIN ISCHEMIA. International Journal of Medicine and Medical Research, 4(1), 60-66. https://doi.org/10.11603/ijmmr.2413-6077.2018.1.9253